UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2008

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	13-3929237
(State or Other Juris-diction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4520 East-West Highway, Suite 300 Bethesda, Maryland		20814
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On September 25, 2008, Sucampo Pharmaceuticals, Inc. delivered an investor conference presentation at the UBS Life Sciences Conference that included written communication comprised of slides. The slides from the presentation at the UBS Life Sciences Conference are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 8.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	Presentation slides for UBS Global Life Sciences Conference, dated September 25, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: September 26, 2008

By: /s/ JAN SMILEK
Name: Jan Smilek
Title: VP, Finance and Acting Chief Financial Officer

SUCAMPO PHARMACEUTICALS, INC.

UBS
Global Life Sciences Conference

Ryuji Ueno, M.D., PhD., PhD.
CEO, CSO, & Co-Founder

September 25, 2008

Safe Harbor

Forward-looking statements contained in this presentation are based on Sucampo's assumptions and expectations concerning future events. They are subject to significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Sucampo's forward-looking statements could be affected by numerous foreseeable and unforeseeable events and developments such as regulatory delays, the failure of clinical trials, the inability to fund drug development initiatives, competitive products and other factors identified in the "Risk Factors" section of Sucampo's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. In light of the significant uncertainties inherent in the forward-looking information in this presentation, you are cautioned not to place undue reliance on these forward-looking statements.

Sucampo Pharmaceuticals, Inc.
A Focused Biopharmaceutical Company

- **AMITIZA®**
  - The only FDA approved drug for **Chronic Idiopathic Constipation** (CIC) in adults of all ages (AMITIZA 24 mcg)
  - The only FDA approved drug for **Irritable Bowel Syndrome with Constipation** for women 18 years and older (AMITIZA 8 mcg)
  - Sucampo sales force of 38 reps for long-term care and academic hospitals
  - Takeda sales force of ~900 reps for GI, primary care and other physicians plus consumer promotion
- **Robust pipeline of future indications and products**
  - Ongoing **AMITIZA** trials for other indications including Opioid-induced Bowel Dysfunction
  - Ongoing proof of concept trials of **cobiprostone** in NSAID-induced Ulcers and Portal Hypertension
  - Moving **SPI-017** towards clinical trials for Peripheral Arterial Disease and Alzheimer's
- **Strong financial position**
  - Profitable operations in 2006, 2007 and YTD 2008
  - $135.0 million in cash and investments as of June 30, 2008

AMITIZA® Fills a Critical Need in the GI Market

Only product approved by FDA for Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C)

•Unique mechanisms of action

- CIC (24 mcg) activates **chloride ion channels** to promote fluid secretion
- IBS-C (8 mcg) activates chloride ion channels and promotes **mucosal barrier protection**

•Proven safety and efficacy for long-term usage

- Competitive products recommended for short-term use only

•Quick and predictable relief of symptoms

- With CIC, **57% - 63%** of patients respond within 24 hours
- IBS-C patients receiving 8 mcg were twice as likely to achieve overall response than those receiving placebo

•Well positioned to capitalize on major market opportunity

- Estimate U.S. market of **12,000,000** patients with CIC
- Estimate more than **19,000,000** patients with IBS-C in the U.S.

AMITIZA® Co-Marketed with Takeda Pharmaceuticals

SUCAMPO PHARMACEUTICALS, INC.

Takeda

Co-Marketing Agreement with Takeda

- Geographic territory: U.S. and Canada
- Indications: covers GI only, with right of first refusal in other therapeutic areas
  - AMITIZA for CIC (24 mcg) approved in January 2006
  - AMITIZA for IBS-C (8 mcg) approved in April 2008
- **$20 million** upfront payment received at signing in October 2004
- **$130 million** in development milestones received as of 6/30/08
- Up to an additional **$60 million** in development and commercial milestone payments
- Cumulative product royalties of **$51.1 million** since launch as of 6/30/08
- Partial reimbursement of Sucampo's direct sales and promotion costs
- Reimbursement for development expenses for additional indications and formulations (up to **$50 million** for each new GI indication and **$20 million** for each new formulation)
- Takeda responsible for commercialization, distribution and consumer promotion
- Sucampo primarily responsible for research and development

AMITIZA® is Supported by a Strong Co-Marketing Alliance in the U.S.

Target: office-based specialty and primary care physicians

- ~900-person sales force
- Managed markets contracting
- Regional science management

amitiza® lubiprostone

Target: Long-term care facilities and key academic medical centers

- 38-person sales force
- Key opinion leader (KOL) clinical experience
- High potential in long-term care segment

Sucampo Sales of AMITIZA
(Institutional Quarterly Sales)



	Q2 07	Q3 07	Q4 07	Q1 08	Q2 08
Long Term Care	$2,466,063	$2,881,549	$3,216,491	$3,471,477	$3,940,633
Hospital	$1,360,922	$1,415,455	$1,423,229	$1,476,945	$1,722,911

Source – IMS DDD Note: Growth rates are quarter over quarter

Weekly AMITIZA® Retail Prescriptions – TRx & NRx 26 Weeks Ending September 12, 2008



Source – IMS Weekly Retail Data

AMITIZA
Ongoing Pediatric Trial for Chronic Idiopathic Constipation (CIC) in U.S.

- A fully enrolled, open-label, study, with 120 pediatric patients
- Treatment period of 4 weeks, plus 4-week follow-up period
- Dose level and frequency of administration is dependent on age and weight:
  - Cohort 1: Adolescents 12-17 years old, dose of 12 mcg twice daily
    - Over 36 kg – receive 24 mcg twice daily
  - Cohort 2: Children 6-11 years old and weighing
    - Between 12 and 24 kg – receive 12 mcg once daily
    - At least 24 kg – receive 12 mcg twice daily
    - Over 36 kg – receive 24 mcg twice daily
  - Cohort 3: Children less than 6 years old, with at least 12 kg body weight, dose of 12 mcg, once daily
- Primary endpoint: frequency of spontaneous bowel movements at end of Week 1
- Anticipate results in First Quarter 2009

AMITIZA
Additional Trials for Hepatic Impairment and Renal Impairment

- **Hepatic Impairment**
  - A multi-center, single-dose study to evaluate the PK parameters in subjects with impaired hepatic function compared with matched healthy volunteers
  - Study initiated in January 2007
  - Treatment period completed
  - Analysis of results ongoing

- **Renal Impairment**
  - A multi-center, single-dose study to evaluate the PK parameters in subjects with impaired renal function compared with matched healthy volunteers
  - Study completed
  - Submitted to FDA in April 2008
  - Results: Single dose of 24 mcg was safe and well tolerated
  - No need for dosage adjustment in CIC patients with impaired renal function

AMITIZA
Two Ongoing Phase 3 Pivotal Trials for Opioid-Induced Bowel Dysfunction (OBD)

- Two ongoing Phase 3 pivotal, randomized, placebo-controlled trials with an identical design
- Currently enrolling 420 patients using opioids chronically for non-malignant pain in each trial
- Oral administration of 24 mcg gel capsule twice daily (total of 48 mcg/day) over 12 weeks, followed by 9-month extension safety study
- Primary endpoint: change from baseline in spontaneous bowel movement frequency at week 8
- Anticipate completion of patient enrollment by year-end 2008

AMITIZA
Successful Phase 3 Trials for CIC in U.S. Support Current Filings in Europe

Chronic Idiopathic Constipation (CIC)

- **European Marketing application submitted to European regulatory agencies in Spring 2008**
  - Using data generated in U.S. phase 3 trials
  - Decentralized application procedure
  - Selected **United Kingdom** as reference member state
  - Additional applications to **Belgium**, **Denmark**, **France**, **Germany**, **Ireland**, **The Netherlands**, **Spain** and **Sweden**

- **Additional marketing application for CIC submitted**
  - **Switzerland** in Summer 2008

AMITIZA
Successful Phase 2b Trial for CIC for Japanese Population*

- A randomized, parallel group, double-blind, placebo-controlled multi-center study
- 170 patients
- Dose levels: 8, 16 or 24 mcg of AMITIZA twice daily
- Primary endpoint: mean change in spontaneous bowel movements (SBM) from baseline after 1 week on treatment

- Results: Safe and well tolerated, and demonstrated a **statistically significant increase of SBM ($p<0.0001$)**
- AMITIZA also demonstrated statistically significant improvement of several secondary endpoints including: change in SBM after Week 2, mean weekly SBM, **degree of straining, abdominal bloating, abdominal discomfort**, global assessment of severity of constipation, global assessment of treatment efficacy as well as a **quality of life evaluation of treatment satisfaction**

** Sucampo Pharmaceuticals, Inc. Press Release Sept. 18, 2008*

AMITIZA® Product Development Milestones

Milestone	Completed	Future
▪ Approval of sNDA for IBS-C in U.S.	✓	
▪ Commercial launch of Amitiza for IBS-C in U.S.	✓	
▪ Submit supplemental label expansion in U.S. for CIC patients with impaired renal function.		2009
▪ Complete analysis of hepatic trial (CIC) and submit supplemental label expansion in U.S.		2008
▪ File for European marketing approvals (decentralized procedure)	✓	
▪ Complete phase 2b study for Japanese population	✓	
▪ Initiate phase 4 study in male and female patients with IBS-C utilizing a higher dose than currently recommended		2009
▪ Initiate study in Pediatric for IBS-C		2009
▪ Complete 2 phase 3 OBD pivotal trials and long term safety study		2009
▪ Complete analysis of Pediatric CIC trial and submit supplemental label expansion in U.S.		2009

Sucampo Retains Global Marketing Rights to Entire Discovery and Development Pipeline



Cobiprostone
Phase 2 Trial to Prevent NSAID-Induced GI Injury

- Two Phase 2 double-blinded, randomized, placebo-controlled, dose-finding trials
- 120 subjects in total
- Three dose levels of cobiprostone
  - 18 mcg one time a day
  - 18 mcg two times a day
  - 18 mcg three times a day
  - All patients receive 500 mg naproxen twice a day

- Primary endpoint: overall incidence of gastric ulcers during 12 Week treatment period
- Anticipate enrollment to complete by year-end 2008
- Market Opportunity: An estimated **3,000,000 NSAID patients in the U.S.** develop gastric ulcers each year

Other Pipeline Development Milestones

Milestone	Completed	Future
Cobiprostone		
▪ **Initiate Ph 2** NSAID-induced ulcer study	✓	
▪ **Initiate Ph 2** study in portal hypertension (proof of concept)	✓	2009
▪ **Complete Ph 2** NSAID-induced ulcer study		
SPI-017		
▪ **Initiate Ph 1 study** (IV formulation) in Peripheral Arterial and Vascular Diseases (PAD)		2008
Other		
▪ Initiate pre-clinical studies on additional compounds		2008

Proprietary Fatty Acids – Prostones – Fuel Sucampo's Deep Product Pipeline



Prostones as a Potassium/Chloride channel activator



Selected Financial Data

(in thousands, except for per share data; unaudited)

	Six Months Ended June 30	
	2008	2007
Total revenue	$81,268	$ 61,895
Net income (loss)	30,381	14,400
Earnings per diluted share	0.72	0.41
Number of shares outstanding – diluted	42,026	35,505
	June 30, 2008	December 31, 2007
Cash and investments	$135,030	$86,511

SUCAMPO PHARMACEUTICALS, INC.

UBS Global Life Sciences Conference

Ryuji Ueno, M.D., PhD., PhD.
CEO, CSO, & Co-Founder

September 25, 2008